ISOLATED TUMOUR CELLS IN OESOPHAGEAL CANCER: APPLYING THE SENTINEL LYMPH NODE CONCEPT

Sarah K Thompson
MD  University of Calgary  1999
FRCSC  Canada  2004
FRACS  Australia  2008

A Thesis presented for the degree of Doctor of Philosophy from the Discipline of Surgery, University of Adelaide, South Australia, Australia
# Table of Contents

**THESIS ABSTRACT**

**THESIS DECLARATION**

**ACKNOWLEDGEMENTS**

**CHAPTER 1: INTRODUCTION**

1.1 CANCER OF THE OESOPHAGUS
   1.1.1 EPIDEMIOLOGY
   1.1.2 AETIOLOGY
   1.1.2.1 Predisposing Conditions
   1.1.2.2 Lifestyle/Habits
   1.1.2.3 Environmental/Dietary Factors
   1.1.3 BARRETT’S OESOPHAGUS
   1.1.4 CLASSIFICATION SYSTEM FOR OESOPHAGEAL ADENOCARCINOMA
   1.1.5 TREATMENT OUTCOMES

1.2 STAGING IN OESOPHAGEAL CANCER
   1.2.1 TNM STAGING SYSTEM
   1.2.2 ADDITIONAL PROGNOSTIC FACTORS
   1.2.2.1 Stratifying pT Stage
   1.2.2.2 Stratifying pN Stage
   1.2.2.3 Circumferential Margin
   1.2.2.4 Pathological Response to Chemoradiotherapy
   1.2.3 LYMPHATIC SPREAD IN OESOPHAGEAL CANCER
   1.2.3.1 Lymphatic Drainage Pathways
   1.2.3.2 Pattern of Lymph Node Dissemination
   1.2.4 EXTENT OF LYMPHADENEXCTOMY
   1.2.5 MOLECULAR MARKERS

1.3 OCCULT TUMOUR DEPOSITS
   1.3.1 INTRODUCTION
   1.3.2 DEFINITIONS
   1.3.3 IMPORTANCE OF OCCULT TUMOUR DEPOSITS

1.4 THE SENTINEL LYMPH NODE CONCEPT
   1.4.1 INTRODUCTION
   1.4.2 MAPPING TECHNIQUES
   1.4.3 DEFINITION OF A SENTINEL LYMPH NODE
   1.4.4 PATHOLOGICAL EXAMINATION OF A SENTINEL LYMPH NODE
   1.4.5 SENTINEL NODE BIOPSY IN OESOPHAGEAL CANCER

1.5 AIMS

**CHAPTER 2: IMPROVING THE ACCURACY OF TNM STAGING IN ESOPHAGEAL CANCER: A PATHOLOGICAL REVIEW OF RESECTED SPECIMENS**

2.1 STATEMENT OF AUTHORSHIP
2.2 ABSTRACT
2.3 INTRODUCTION
2.4 MATERIALS AND METHODS
   2.4.1 PATIENT SELECTION
   2.4.2 PREOPERATIVE STAGING AND SURGERY
4.10.1 LETTER TO EDITOR 138
4.10.2 AUTHOR REPLY 140

CHAPTER 5: FEASIBILITY STUDY OF SENTINEL LYMPH NODE BIOPSY IN ESOPHAGEAL CANCER WITH CONSERVATIVE LYMPHADENECTOMY 143

5.1 STATEMENT OF AUTHORSHIP 144
5.2 ABSTRACT 146
5.3 INTRODUCTION 147
5.4 MATERIALS AND METHODS 149
5.4.1 PATIENT SELECTION AND PREPARATION FOR SURGERY 149
5.4.2 LYMPHOSCINTIGRAPHY AND SURGERY 149
5.4.3 SPECIMEN HANDLING AND PATHOLOGY 150
5.4.4 STATISTICAL ANALYSIS 151
5.5 RESULTS 152
5.5.1 PATIENT AND TUMOR CHARACTERISTICS 152
5.5.2 LYMPHOSCINTIGRAPHY 152
5.5.3 ACCURACY OF SENTINEL LYMPH NODE(S) 153
5.6 DISCUSSION 154
5.6.1 CHOICE OF RADIOACTIVE TRACER 156
5.6.2. PREOPERATIVE ENDOSCOPY & PERITUMORAL INJECTION 157
5.6.3. IN VIVO IDENTIFICATION OF SENTINEL LYMPH NODE(S) 157
5.6.4. DEFINITION OF SENTINEL LYMPH NODE 158
5.6.5. EX-VIVO IDENTIFICATION OF SENTINEL LYMPH NODE(S) 159
5.6.6. PATHOLOGICAL ANALYSIS 159
5.7 CONCLUSION 160
5.8 ACKNOWLEDGMENTS 160
5.9 REFERENCES 161
5.10 PUBLISHED QUESTIONS & ANSWERS 169
5.10.1 DISCUSSANT 169
5.10.2 AUTHOR REPLY 170

CHAPTER 6: SENTINEL LYMPH NODE BIOPSY IN ESOPHAGEAL CANCER: SHOULD IT BE STANDARD OF CARE? 173

6.1 STATEMENT OF AUTHORSHIP 174
6.2 ABSTRACT 175
6.3 INTRODUCTION 176
6.4 MATERIALS AND METHODS 178
6.4.1 PATIENT SELECTION AND PREPARATION FOR SURGERY 178
6.4.2 LYMPHOSCINTIGRAPHY AND SURGERY 178
6.4.3 SPECIMEN HANDLING AND PATHOLOGY 179
6.4.4 STATISTICAL ANALYSIS 180
6.5 RESULTS 181
6.5.1 PATIENT AND TUMOR CHARACTERISTICS 181
6.5.2 SENTINEL NODE IDENTIFICATION 181
6.5.3 ACCURACY OF SENTINEL LYMPH NODE(S) 182
6.6 DISCUSSION 184
6.7 CONCLUSION 188
6.8 ACKNOWLEDGMENTS 188
6.9 REFERENCES 189

CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS 197

7.1 CONCLUSIONS 198
7.1.1 AIM # 1 198
7.1.2  AIM #2  199
7.1.3  AIM #3  200
7.1.4  AIM #4  201

7.2  FUTURE DIRECTIONS  203
7.2.1  LIMITATIONS OF CURRENT SENTINEL LYMPH NODE TRACERS  203
7.2.2  NANOTECHNOLOGY  204
7.2.3  PROPOSED STUDY DESIGN  205
7.2.3.1  Aims  205
7.2.3.2  Hypotheses  205
7.2.3.3  Methods  205
7.2.4  PROPOSED RESEARCH TEAM  207

BIBLIOGRAPHY  209
## Table of Figures

| Figure | Description                                                                                                                                                                                                 | Page |
|--------|--------------------------------------------------------------------------------------------------------------------------------Adam Carino| 19   |
| Figure 1.2 | AJCC/UICC: TNM Staging for Oesophageal Carcinoma (6th Edition)                                                                                                                                 | 21   |
| Figure 1.3 | Extracapsular Lymph Node Invasion of a Lymph Node with H&E Staining                                                                                                                                               | 24   |
| Figure 1.4 | Terminology for Lymphadenectomy in Oesophageal Cancer                                                                                                                                                             | 27   |
| Figure 1.5 | Lymph Nodes Removed in a Two-Field (A) vs Conservative (B) Procedure                                                                                                                                              | 29   |
| Figure 1.6 | UICC Definitions for Occult Tumour Deposits                                                                                                                                                                       | 32   |
| Figure 1.7 | A Micrometastasis (A) and an Isolated Tumour Cell (Arrow, B) in an Oesophageal Cancer Lymph Node, Using IHC with AE1/AE3                                                                                     | 33   |
| Figure 1.8 | Correct Technique for Peritumoural Injection of RadioColloid                                                                                                                                                     | 36   |
| Figure 1.9 | Navigator™ Gamma Guidance System                                                                                                                                                                                  | 37   |
| Figure 1.10 | Labelled Pots with Separate Lymph Node Stations for Pathological Analysis                                                                                                                                       | 38   |
| Figure 2.1 | Survival According to pTNM-Stage for 240 Oesophageal Cancer Patients                                                                                                                                              | 66   |
| Figure 2.2 | Survival for 240 Oesophageal Cancer According to Number of Involved Lymph Nodes                                                                                                                                  | 67   |
| Figure 2.3 | Survival According to Treatment Response After Neoadjuvant Therapy for 124 Oesophageal Cancer Patients                                                                                                           | 68   |
| Figure 3.1 | Study Population                                                                                                                                                                                                    | 97   |
| Figure 3.2 | Oesophageal Adenocarcinoma Tissue Microarrays Showing HER2 Protein Expression (AE1/AE3 IHC) and HER2 Gene Amplification (SISH)                                                                                  | 98   |
| Figure 3.3 | Survival According to the Presence or Absence of HER2 Gene Amplification for 89 Oesophageal Adenocarcinoma Patients                                                                                              | 99   |
| Figure 4.1 | Lymph Node Section Showing No Overt Metastatic Cells (A, H&E), and Obvious Isolated Tumor Cells (B, AE1/AE3 IHC)                                                                                            | 129  |
| Figure 4.2 | Characteristics of Isolated Tumor Cells (AE1/AE3 IHC)                                                                                                                                                             | 130  |
| Figure 4.3 | Survival According to the Presence or Absence of Occult Tumor Deposits for Node Negative Oesophageal Cancer Patients (n = 119)                                                                                 | 131  |
| Figure 4.4 | Survival for Isolated Tumor Cells Versus Isolated Tumor Clusters                                                                                                                                                 | 132  |
| Figure 4.5 | Survival According to the Presence or Absence of Occult Tumor Deposits for Node Negative Oesophageal Cancer Patients Treated with Neoadjuvant Therapy                                                             | 133  |
| Figure 6.1 | Location of Sentinel Lymph Nodes in 29 Oesophageal Cancer Patients                                                                                                                                                 | 194  |
Table of Tables

**Table 2.1.** Survival according to patients’ and tumor characteristics (n = 240) on univariate Cox regression

**Table 2.2.** Survival according to tumor pathology and pTNM stage (n = 240) on univariate Cox regression

**Table 2.3A.** Prognostic factors for survival after resection for esophageal cancer from multivariate Cox regression (n = 227)

**Table 2.3B.** Prognostic factors for survival after resection for esophageal cancer in neoadjuvant therapy subset (n = 112)

**Table 2.4.** Subset analysis of survival in patients with neoadjuvant therapy (n=124)

**Table 2.5.** Subset analysis of survival in patients with no neoadjuvant therapy (n=116)

**Table 2.6.** Goodness of fit and predictive accuracy of prognostic variables for esophageal cancer

**Table 3.1.** Patient and tumor characteristics

**Table 3.2.** Incidence of HER2/NEU amplification and IHC expression in esophageal adenocarcinoma

**Table 3.3.** Association between patient and tumor characteristics and HER2/NEU amplification in esophageal adenocarcinoma (n = 89)

**Table 3.4.** Comparative data for SISH HER2/NEU gene copy status and HER2 IHC in esophageal adenocarcinoma

**Table 4.1.** Correlation between patient and tumor characteristics and AE1/AE3 positivity (n = 119)

**Table 4.2.** Survival according to presence of isolated tumor cells or micrometastases in lymph nodes

**Table 4.3.** Differences in survival across the 4 tumor deposit groups (n = 119)

**Table 4.4.** Multivariate analysis for node negative esophageal cancer patients

**Table 5.1.** Sentinel lymph node characteristics in 16 patients

**Table 5.2.** Technical considerations for sentinel lymph node biopsy and same-day esophagectomy

**Table 6.1.** Patient and tumor characteristics (n= 31)

**Table 6.2.** Accuracy of the sentinel node (n=29)
THESIS ABSTRACT

INTRODUCTION: Accurate staging of oesophageal cancer is critical in predicting prognosis and tailoring therapy. However, the current TNM based staging system is suboptimal because it combines patients with very different outcomes into each disease stage. Our aims are to identify pathological factors or molecular markers that can significantly improve the accuracy of the oesophageal cancer staging system by both a retrospective database review as well as detailed analysis of oesophageal cancer specimens. The benefit of incorporating sentinel lymph node biopsy with oesophageal resection will also be determined.

METHODS: 240 patients (mean age, 62 yrs) were identified from an Oesophageal Cancer database between 1997 and 2007. We re-examined all pathology slides from the original resection to identify significant prognostic factors, and to determine suitable paraffin blocks for the remaining parts of the study. Tissue microarrays were constructed from 89 paraffin blocks for HER2 gene amplification by silver-enhanced in situ hybridization (SISH). Incidence of HER2 positivity, and correlation to clinicopathological variables were determined. Of the original 240 patients, we identified 119 patients who were classified as node-negative. Additional sections with immunohistochemistry (IHC) staining were performed on the relevant paraffin blocks. The yield of occult tumour deposits was determined along with their prognostic significance. Thirty-one consecutive oesophageal cancer patients underwent resection and sentinel lymph node retrieval. Endoscopic peritumoural injection of $^{99m}$Tc antimony colloid was performed, and sentinel lymph nodes were identified and sent off separately for serial sections and IHC.
RESULTS: The 5-year overall survival rate was 36% (median, 24 months). Only histological grade and refined nodal status were found to be independent prognostic factors. True HER2 gene amplification was detected in 14 (16%) oesophageal cancer specimens. No significant associations were found among gene amplification, clinicopathological factors, or survival. Of 119 node negative patients, 31 patients (26%) were found to have occult tumour deposits with serial sections and IHC. Five-year survival rates were 60% for patients who remained node-negative, 33% for patients with isolated tumor cells, 40% for patients with micrometastases, and 0 for the patient with a metastasis ($P=0.02$). At least one sentinel lymph node (median, 3) was identified in 29 of 31 patients (success rate, 94%). In 28 of 29 patients, the sentinel lymph node accurately predicted findings in non-sentinel nodes (accuracy, 96%).

CONCLUSIONS: A staging model in oesophageal cancer which incorporates refined nodal status and histological grade appears to be more accurate than the current TNM staging system. While molecular targeting may be possible for approximately 16% of oesophageal adenocarcinoma patients, HER2 oncogene amplification was not associated with any affect on survival in this study. Almost one third of all node negative patients had occult tumour deposits in their nodes that were missed on their original pathology. Surprisingly, even those with isolated tumour cells had a significantly worse prognosis than those without. Sentinel lymph node biopsy seems to be feasible and accurate in predicting overall nodal status. It improves staging accuracy and should therefore become standard of care in the surgical treatment of patients with oesophageal cancer.
THESIS DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Sarah K Thompson and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis (as listed below) resides within the copyright holders of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Signed _______  ___________  Date 22. MARCH. 2011
PUBLISHED WORKS

- Published by Springer Science + Business Media, LLC © 2008 The Society of Surgical Oncology, Inc. The original publication, DOI http://dx.doi.org/10.1245/s10434-008-0155-0, is available at www.springer.com.

- Published by Springer Science + Business Media, LLC © 2011 The Society of Surgical Oncology, Inc. The original publication, DOI http://dx.doi.org/10.1245/s10434-011-1554-1, is available at www.springer.com.

- Published by Wolters Kluwer Health © 2010 by Lippincott Williams & Wilkins. The original publication, DOI http://dx.doi.org/10.1097/SLA.0b013e3181e61e15, is available at www.lww.com.

- Published by Springer New York © Springer Science + Business Media LLC 2011. The original publication, DOI: http://dx.doi.org/10.1007/s00464-010-1265-x, is available at www.springerlink.com.

- Published by Springer New York © Springer Science + Business Media LLC 2011.
ACKNOWLEDGEMENTS

This work was started while the author was a Clinical Research Fellow in the Professorial Oesophago-Gastric Unit at the Royal Adelaide Hospital, under the guidance of Professor Glyn Jamieson and Dr Andrew Ruszkiewicz in 2006. In 2008, after becoming a Consultant Surgeon on the Unit, we obtained sponsorship to proceed with the latter 3 parts of the study. A 2008 Royal Adelaide Hospital/IMVS Project Grant (valued at $21,000), a 2008 Society of American Gastroenterologists and Endoscopic Surgeons Research Grant (valued at $19,000), and a Royal College of Australasian Surgeons AstroZeneca Grant (valued at $11,000) sponsored the various aspects of the study.

I would like to thank Professor Glyn Jamieson and A/Professor Peter Devitt for having an “open-door” policy to discuss questions and problems along the way. I am indebted to Dr Andrew Ruszkiewicz for his enthusiasm and support in participating in this work. I have learned so much from him about the nuances of Surgical Pathology. I also thank Mr Peter Lamb, our Fellow in 2009, who was instrumental in teaching me his technique for sentinel lymph node biopsy during oesophageal resection, and Dr Dylan Bartholomeusz for showing up to every one of our theatre sessions to transport the radioactive tracer! I appreciate the willingness of Mr Philip Game and Mr Andrew Lord to allow their patients to be included in the study, and the Pathology staff and theatre staff without whom this work would be non-existent.

Finally, I would like to thank Tim for his patience, objective advice, humour, and great cooking (!) without all of which I would not have finished this work. I thank my sister Rachel who has attended all of my local conference talks, Molly the spoodle for her excellent company, and my parents Jan and Ken for their keen “interest” in my thesis (i.e. great listening skills) and the many long-distance phone calls.